InTone for Urinary Incontinence

Sponsor
University Health Network, Toronto (Other)
Overall Status
Unknown status
CT.gov ID
NCT02543242
Collaborator
(none)
30
1
1
13
2.3

Study Details

Study Description

Brief Summary

The rationale for the conduct of this study is that the Intone device (along with pelvic physiotherapy) can be used to help females suffering from urinary stress incontinence by using electrical stimulation and biofeedback during pelvic floor muscle training. This investigation is important because it can aid in the greater acceptance and development of non-surgical treatments for Stress Urinary Incontinence if these areas are looked into. The study results will address if the Intone device is beneficial and promotes long-term improvement in women that suffer from urinary incontinence.

Condition or Disease Intervention/Treatment Phase
  • Device: InToneTM (InControl Medical, LLC) - Medical Device
N/A

Detailed Description

Urinary incontinence is very common in women and is linked to a reduced quality of life (Corcos et al., 2002). The three main types of urinary incontinence are Stress Urinary Incontinence (SUI), Urge Urinary Incontinence (UUI) and Mixed Urinary Incontinence (MUI). SUI and UUI involve losing urine involuntarily. In SUI this is during either effortful motion such as coughing or sneezing, or in UUI is associated with a feeling of urgency. Urinary incontinence has various treatment options including: surgery, medication, pelvic floor muscle exercises and electrical stimulation (Norton & Brubaker, 2006).

The most common physiotherapy treatment used for women with urinary incontinence is pelvic floor muscle training (Dumoulin & Hay-Smith, 2010). Several studies have investigated the effects of PFMT in comparison to other treatments such as no treatment and vaginal cones. They found that women in the PFMT group reported more improvement and better quality of life than women in other treatment groups. The PFMT group also had fewer daily incontinence episodes and less leakage (Bø, Talseth, & Holme, 1999; Dumoulin & Hay-Smith, 2010).

Electrical stimulation of the pelvic floor muscles is another treatment for urinary incontinence, and may often be combined with PFMT. Success rates of electrical stimulation in treating urinary incontinence range from 50-90% (Bent et al., 1993; Erikson, Bergmann, & Mjølnerød, 1987; Fall, 1984; Pelvnik et al., 1986).

A new product has been developed called InTone which combines PFMT, electrical stimulation and biofeedback. This device is inserted into the vagina and facilitates PFMT while providing electrical stimulation and biofeedback to the patient. This study will examine the effectiveness of the InTone device in treating urinary incontinence in women.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effectiveness of the Intone Pelvic Floor Device for Urinary Incontinence
Study Start Date :
Aug 1, 2015
Anticipated Primary Completion Date :
Sep 1, 2016
Anticipated Study Completion Date :
Sep 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

Participants will undergo the InTone TM (InControl Medical, LLC) medical device treatment for Urinary Incontinence. The frequency of treatment is once/day (12 minutes), 5-6 days/week. The route of administration is vaginal.

Device: InToneTM (InControl Medical, LLC) - Medical Device

Outcome Measures

Primary Outcome Measures

  1. Pad Test Weighting [up to 26 weeks]

    urine voiding measure

Secondary Outcome Measures

  1. Urinary Distress Inventory (UDI-6) [screening, Device Set up/Training Day, 2, 6, 14, 26 weeks from set up.]

    Questionnaire that assesses symptom distress and the impact on daily life of urinary incontinence

  2. Incontinence Impact Questionnaire Short Form (IIQ-7) [screening, Device Set up/Training Day, 2, 6, 14, 26 weeks from set up.]

    Assesses symptom distress and the impact on daily life of urinary incontinence

  3. Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12) [screening, Device Set up/Training Day, 2, 6, 14, 26 weeks from set up.]

    Evaluates sexual function in women with pelvic organ prolapse and/or urinary incontinence.

  4. Urinary Incontinence Quality of Life Scale (IQOL) [screening, Device Set up/Training Day, 2, 6, 14, 26 weeks from set up.]

    A self-reported quality of life measure specific to urinary incontinence (UI),

  5. International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ UI SF) [screening, Device Set up/Training Day, 2, 6, 14, 26 weeks from set up.]

    A subjective measure of severity of urinary loss and quality of life for those with urinary incontinence.

  6. 48 Hour Bladder Diary [up to 6 months follow-up]

    A diary containing details of every void. The time, amount leaked and activity during the leakage are recorded for 48 hours.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Female gender

  • Between ages 18-70

  • Diagnosed with Stress Urinary Incontinence (SUI), Urge Urinary Incontinence (UUI), or Mixed Urinary Incontinence (MUI)

Exclusion Criteria:
  • Incontinence of less than 6 months

  • pregnancy or delivery within 6 weeks

  • vaginal or pelvic surgery within previous 6 months

  • pelvic organ prolapse greater than stage 2 (based on POP-Q)

  • active UTI or history of recurrent UTIs (more than 3 in a year)

  • recurrent vaginitis (bacterial/fungal)

  • pelvic pain/painful bladder syndrome

  • implanted cardiac device or untreated cardiac arrhythmi

  • Underlying neurologic/neuromuscular disorder, or inadequate vaginal caliber (can't accommodate device).

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Health Network (Altum Health) Toronto Ontario Canada M5T 2S8

Sponsors and Collaborators

  • University Health Network, Toronto

Investigators

  • Principal Investigator: Dean S Elterman, MD, University Health Network, Toronto

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT02543242
Other Study ID Numbers:
  • InTone
First Posted:
Sep 7, 2015
Last Update Posted:
Sep 7, 2015
Last Verified:
Sep 1, 2015
Keywords provided by University Health Network, Toronto
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 7, 2015